Avadel Pharmaceuticals plc Ordinary Share

Compare this stock

AVDL Stock Report Card

Today's performance

43%

Performance

Score:

100/100

AVDL returned 58.04% in the last 12 months. Based on SPY's performance of -21.06%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

Score:

80/100

5 analysts offer 12-month price targets for AVDL. Together, they have an average target of 10.67, the most optimistic target put AVDL at 12 within 12-months and the most pessimistic has AVDL at 9.

Sentiment

Score:

70/100

AVDL had a bullish sentiment score of 70.23% across Twitter and StockTwits over the last 12 months. It had an average of 6.78 posts, 3.03 comments, and 4.97 likes per day.

Technicals

Score:

11/100

AVDL receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

Score:

10/100

AVDL has missed earnings 7 times in the last 20 quarters.

Profit

Score:

10/100

Out of the last 20 quarters, AVDL has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

Score:

56/100

AVDL has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.

Avadel Pharmaceuticals plc Ordinary Share Summary

Nasdaq / AVDL

Healthcare

Drug Manufacturers - Specialty & Generic

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Power up your portfolio